Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis

Authors
Category Primary study
Year 2008
INTERVENTION: Docetaxel plus zoledronic acid Docetaxel CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: Progression free survival SECONDARY OUTCOME: Safety, Response rate, SRE rate, SRE free survival, Over all survival INCLUSION CRITERIA: >NSCLC with bone metastasis >Previous treatment with one or two chemotherapy regimens >Measurable lesion >Adult patients (>20 years of age) >Performance status 0‐2 >Adequate organ functionWritten informed consent
Epistemonikos ID: 1ff2d084ccee0ea42513f7e83cc65c15a92ca2fa
First added on: Aug 21, 2024